Under the Paperwork Reduction Act of 1995, no persons are require

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10693700		
	Filing Date		2003-10-24		
First Named Inventor Ches		Ches	ter Ledlie Sandberg		
	Art Unit		3742		
	Examiner Name S. Y.		Paik	_	
	Attorney Docket Number		5659-21000/TH2559	_	

U.S.PATENTS Remove								
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6997518		2006-02-14	Vinegar et al.			
	2	7036583		2006-05-02	de Rouffignac et al.			
	3	7011154		2006-03-14	Maher et al.			
	4	7004251		2006-02-28	Ward et al.			
	5	7004247		2006-02-28	Cole et al.			
	6	3051235		1962-08-28	Banks			
	7	4446917		1984-05-08	Todd			
	8	4385661		1983-05-31	Fox			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Filing Date First Named Inve

Ī	Application Number		10693700		
	Filing Date		2003-10-24		
	First Named Inventor Ches		er Ledlie Sandberg		
	Art Unit		3742		
	Examiner Name S. Y.		Paik		
	Attorney Docket Number		5659-21000/TH2559		

	9 4199024			1980-04-22 Rose et al.		
	10	6994169		2006-02-07	Zhang et al.	
	11	6994160		2006-02-07	Wellington et al.	
	12	6994168		2006-02-07	Wellington et al.	
	13 6997255 2006-02-1-		2006-02-14	Wellington et al.		
	14	2997105	1961-08-22		Campion et al.	
	15 7040397		2006-05-09		de Rouffignac et al.	
	16	7040398		2006-05-09	Wellington et al.	
	17	7040399		2006-05-09	Wellington et. al.	
	18	7040400		2006-05-09	de Rouffignac et al.	
If you wis	h to ac	dd additional U.S. Paten			ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10693700		
iling Date		2003-10-24		
irst Named Inventor	Ches	ter Ledlie Sandberg		
rt Unit		3742		
xaminer Name	S. Y.	Paik		
ttorney Docket Numb	er	5659-21000/TH2559		

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant Re		Relev	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	20060005968		2006-01-12		Vinegar et al.					
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto	n. Add		
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Cite Foreign Document Country Kind Number ³ Code ² i Code ⁴ Date			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		Ts				
	1										
If you wish	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	buttor	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dity and/or country where published.								Τs		
	HT10 U.S. Patent and Trademark Office, "Office Communication," for U.S. Application Serial No. 10/279,288 mailed March 16, 2006: 5 pages (available in Public Pair)										

A

E

EXAMINER SIGNATURE

Examiner Signature

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not nonformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

See Kinz Codes of USPTO Patient Documents at year USPTO_CODE or MPEP 901.6. If Earls office that assed the document, by the hole left code (WIPO Standard ST.3). Sort Justinese plants from Counterful, by a finite of the Person of the Person

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date		10693700		
		2003-10-24		
First Named Inventor	Ches	ster Ledlie Sandberg		
Art Unit		3742		
Examiner Name	S. Y.	Paik		
Attorney Docket Number		5659-21000/TH2559		

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.	97 and 1.	98 to make the	e appropriate	selection(s):
---------------	----------	-----------	----------------	---------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☑ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Eric B. Meyertons/	Date (YYYY-MM-DD)	2006-05-24
Name/Print	Eric B. Meyertons	Registration Number	34876

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.